8th Annual Single Cell Analysis Congress04 - 06 November 2020, GMT (UTC+0)

Organisations at the forefront of this field will present case studies on Single Cell ‘Omics Analysis, Spatial Transcriptomics, Single Cell analysis in Drug Discovery and Development, as well as overcoming sample preparation and bioinformatics challenges.

Last Year's Event Included...

Over 800 attendees representing internationally renowned academic institutions, research institutes and hospitals as well as global pharmaceutical organisations and leading biotech companies.

Over 40 case studies, presentations, panel discussions focused on the key issues in spatial transcriptomics, advanced tools, their applications in clinical use and drug discovery & development.

PLUS interactive opportunities including:

  • Panel Discussions
  • Pre-Event Webinars
  • Pre-Event Speaker Q&As and Spotlights

Agenda at a Glance

Pre-Event Deep Dive Session

  • Microbiome Methodologies
  • Single Cell Proteomics
  • Clinical Diagnostics & Precision Medicine Multi-Technology Session

Day One

  • Spatial Omics: Spatial Transcriptomics, Genomics & Spatial Profiling
  • Single Cell Omics Analysis: Current & Emerging Tools and Data Analysis

Day Two

  • Applications in Clinical Use
  • Single Cell Analysis in Drug Discovery & Development

Live Webinar

Genomic Testing Strategies For Research Through To Clinical Studies: Profiling Of Genomics From NeoGenomics' Perspective

As genomic technologies develop and mature, adoption moves from the research environment into the clinical setting.  Previously, where Sanger and qPCR were the most rational choices to commercialize a diagnostic, NGS has become the biomarker testing methodology of choice.  Additionally, other emerging technologies and platforms like NanoString are finding their way into clinical trials as well as routine diagnostics.  With advances in technology, biomarker testing strategies have also evolved with a trend toward higher order multiplexed technologies as well as cross modality testing from a single sample to understand correlations between DNA, RNA and protein markers.  More data may be over burdensome to analyze, while a focused assay may miss an opportunity for collecting potentially valuable data.  Without a straightforward “rule of thumb” for which genomics technology to use when, thoughtful consultation is required.  This presentation will discuss the various factors and consideration points for choosing a genomic biomarker testing strategy to support biomarker projects.

Presented by James Yen, Senior Scientific Manager, CDx Programs, NeoGenomics

Thursday, 25 June 2020 | 15:30 BST